BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies

Apoptosis is an essential characteristic of cancer and its dysregular promotes tumor growth, clonal evolution, and treatment resistance. B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition of the BCL-2 family pro-survival protein...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mariam Markouli, Maria N. Pagoni, Panagiotis Diamantopoulos
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	Bcl-2 inhibitors venetoclax apoptosis chronic lymphocytic leukemia acute myeloid leukemia DLBCL
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1501950/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01)

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
by: Sofija Kozarac, et al.
Published: (2025-01-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations
by: Zahra Koolivand, et al.
Published: (2025-01-01)

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
by: Xuelian Jin, et al.
Published: (2025-01-01)

Anuric Acute Kidney Injury in Chronic Myeloid Leukemia: A Rare Complication Case
by: Angela Kimberly Tjahjadi, et al.
Published: (2024-10-01)

ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY
by: Andrea Nunzi, et al.
Published: (2024-06-01)

Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01)

Hematological profile and its correlation with reverse transcription–polymerase chain reaction-based serial quantitative detection of BCR-ABL in chronic myeloid leukemia patients at a referral cancer center
by: Vanita Pandey, et al.
Published: (2024-12-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Lysophosphatidylcholine Acyltransferase 1 (LPCAT1): A Predictor of Acute Leukemia Prognosis
by: Arefeh Mazhari, et al.
Published: (2025-01-01)

Clinical pathological characteristics and prognosis of orbital myeloid sarcoma-a single center retrospective study with 14 Chinese patients
by: Tianyi Zhou, et al.
Published: (2025-01-01)

6-month survival of patients with acute myeloid leukemia who received modified chemotherapy at Wahidin Sudirohusodo Hospital
by: Edwinda D. Ratu, et al.
Published: (2024-09-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Laboratory analysis of 124 chronic lymphocytic leukemia cases: Single center study
by: Shams Salah Mahdi, et al.
Published: (2024-12-01)

Clinico-hematological and immunophenotypic profile of acute leukemia of ambiguous lineage: A four year experience from a single tertiary care centre of West India
by: Varnika Rai, et al.
Published: (2023-07-01)

NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia
by: Qing Zhu, et al.
Published: (2025-12-01)

Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
by: Taha Ulutan Kars, et al.
Published: (2024-02-01)

Bioinformatics Interpretation of Exome Sequencing: Blood Cancer
by: Jiwoong Kim, et al.
Published: (2013-03-01)

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia
by: Rui Zhang, et al.
Published: (2025-02-01)

Spontaneous splenic rupture in a teenager as first manifestation of acute myeloid leukemia: Case report and literature review
by: Antonio Villa, et al.
Published: (2018-11-01)

Cytogenetics and Molecular Abnormalities in Pediatric Patients with Acute Myeloid Leukemia in a Referral Center in Tehran, Iran
by: Mahshid Heidary Sadegh, et al.
Published: (2025-01-01)

Critically ill adult patients with acute leukemia: a systematic review and meta-analysis
by: Dara Chean, et al.
Published: (2025-01-01)

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
by: Lucas Touzet, et al.
Published: (2019-03-01)

Elucidation of the Molecular Interaction between miRNAs and the Gene, Involved in Acute Myeloid Leukemia, by the Assistance of Argonaute Protein through a Computational Approach
by: Rohit Pritam Das, et al.
Published: (2015-06-01)

A Nomogram Built on Clinical Factors and CT Attenuation Scores for Predicting Treatment Response of Acute Myeloid Leukemia Patients
by: Linna Liu, et al.
Published: (2025-01-01)

Case report: Mucormycosis due to Rhizopus microsporus: an important reminder of opportunistic infections in immunocompromised acute myeloid leukemia
by: Misato Higuchi, et al.
Published: (2025-01-01)

Disulfidptosis-related lncRNA signature to assess the immune microenvironment and drug sensitivity in acute myeloid leukemia
by: Yuying Zhao, et al.
Published: (2024-12-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
by: Meng-Tung Hsu, et al.
Published: (2025-01-01)

Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors
by: Fersing Cyril, et al.
Published: (2022-03-01)

Lysine (K)-specific methyltransferase 2A (KMT2A) rearrangements among Iraqi de novo acute myeloid leukemia
by: Riyam Qusay Al Jadir, et al.
Published: (2024-12-01)

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01)

Identification of biomarkers for chronic lymphocytic leukemia risk: a proteome-wide Mendelian randomization study
by: Changyu Jin, et al.
Published: (2025-01-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)